RecruitingNCT05650619
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Studying Idiopathic multidrug-resistant nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Michigan
- Principal Investigator
- Eloise Salmon, MDUniversity of Michigan
- Intervention
- Biospecimen collection(other)
- Enrollment
- 300 enrolled
- Eligibility
- All sexes
- Timeline
- 2022 – 2026
Study locations (1)
- University of Michigan, Ann Arbor, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05650619 on ClinicalTrials.govOther trials for Idiopathic multidrug-resistant nephrotic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06664814An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental GlomerulosclerosisNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE3NCT07220083A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Boehringer Ingelheim
- RECRUITINGPHASE2NCT07268638A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)Akebia Therapeutics
- RECRUITINGPHASE2NCT06500702A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseSanofi
- RECRUITINGPHASE1, PHASE2NCT06090227AMPK-activation by Metformin in FSGS: AMP-FSGSYale University
- RECRUITINGNANCT04065438Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 SystemKaneka Medical America LLC
- ACTIVE NOT RECRUITINGPHASE3NCT03493685Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Travere Therapeutics, Inc.
- RECRUITINGNANCT02235857Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenKaneka Medical America LLC
See all trials for Idiopathic multidrug-resistant nephrotic syndrome →